therapeutics

Adenosine monophosphate-activated protein kinase: A golden mediator of exercise in metabolic dysfunction-associated diseases (review).

Metabolic diseases represent a major threat to human health and are largely associated with excessive energy intake and insufficient energy expenditure. Increasing evidence indicates that obesity, diabetes, metabolic dysfunction-associated fatty liver disease, sarcopenia, Alzheimer's disease, and cancer are closely associated...

🗓️ 2026-08-05
📰 Publication: International Journal Of Biological Macromolecules
Read MoreAdenosine monophosphate-activated protein kinase: A golden mediator of exercise in metabolic dysfunction-associated diseases (review).

A C. elegans-to-Mouse Discovery Framework for Prioritizing Sarcopenia Interventions.

Sarcopenia is a manifestation of musculoskeletal aging, yet no approved therapy is available. A major challenge is not the lack of potential interventions, but the difficulty of efficiently identifying which candidates should advance to aged-mammal validation. Sarcopenia is driven by...

🗓️ 2026-07-28
📰 Publication: Aging And Disease
Read MoreA C. elegans-to-Mouse Discovery Framework for Prioritizing Sarcopenia Interventions.

Therapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice.

Cancer cachexia is a life-threatening wasting syndrome that can be driven by tumor-derived GDF15 signaling through the brainstem-restricted receptor GFRAL. Despite its clinical importance, central genetic interventions targeting this axis remain limited. Here, we develop a potent antisense oligonucleotide (Gfral-ASO,...

🗓️ 2026-07-28
📰 Publication: Cell Reports Medicine
Read MoreTherapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice.

YAP1-Driven Pathogenic Fibro-Adipogenic Progenitors Secrete IL-6 and FGF21 to Mediate Muscle-Bone Crosstalk and Promote Bone Loss.

Sarcopenia, an age-related degenerative disease of skeletal muscle, is closely associated with osteoporosis and other bone disorders, partly due to dysregulated endocrine function of skeletal muscle. However, the specific cellular sources and molecular mechanisms driving this pathological secretory phenotype remain...

🗓️ 2026-07-27
Read MoreYAP1-Driven Pathogenic Fibro-Adipogenic Progenitors Secrete IL-6 and FGF21 to Mediate Muscle-Bone Crosstalk and Promote Bone Loss.

Selective Small-Molecule AdipoR1 Agonist 3-Hydroxy Pterocarpan Salt (CDRI-1709S) Ameliorates Skeletal Muscle Atrophy.

BACKGROUND

Skeletal muscle atrophy is a frequent comorbidity of metabolic disorders and chronic diseases, and despite its high prevalence, no pharmacological therapy is available, representing a major unmet clinical need. Adiponectin and its receptors are key regulators of skeletal muscle metabolism,...

🗓️ 2026-07-22
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSelective Small-Molecule AdipoR1 Agonist 3-Hydroxy Pterocarpan Salt (CDRI-1709S) Ameliorates Skeletal Muscle Atrophy.

Understanding cachexia and muscle dysfunction in the context of metastatic breast cancer.

Cancer cachexia significantly impacts the quality of life of cancer patients, predicting therapy response and survival. Cachexia prevalence and severity increases over the course of disease progression, affecting up to 80% of patients with metastatic cancer. Despite this, cachexia is...

🗓️ 2026-07-18
📰 Publication: Cancer And Metastasis Reviews
Read MoreUnderstanding cachexia and muscle dysfunction in the context of metastatic breast cancer.

Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity.

BACKGROUND

Highly effective anti-obesity medications (AOMs) induce substantial weight loss and have renewed debate on appropriate treatment targets. Weight loss comprises reductions in fat mass (FM) and fat-free mass (FFM), with skeletal muscle (SM) as the major component of FFM. Clinical...

🗓️ 2026-07-15
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDefining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity.

Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition.

Sarcopenia is the age-related loss of muscle strength and size that leads to mobility limitations and loss of independence in older adults. The underlying cellular mechanisms remain unclear, and treatments are limited. As the critical interface between the nervous system...

🗓️ 2026-07-09
📰 Publication: Journal Of Clinical Investigation
Read MoreNeuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition.

Downstream Pathways of Dystrophin Deficiency in Duchenne Muscular Dystrophy: Implications for Muscle Degeneration and Regeneration.

BACKGROUND

Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy, primarily affecting skeletal muscle and leading to premature death. Although the loss of dystrophin has long been recognised as the primary cause of the disease, no...

🗓️ 2026-07-04
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDownstream Pathways of Dystrophin Deficiency in Duchenne Muscular Dystrophy: Implications for Muscle Degeneration and Regeneration.

Li-ginseng powder alleviates cancer cachexia in mice by regulating the ubiquitin-proteasome pathway and reducing inflammation.

BACKGROUND

As a debilitating syndrome, cancer cachexia (CC) manifests as ongoing weight reduction and skeletal muscle atrophy, which severely compromise patients' well-being and life expectancy, with no approved treatment available to date. Rare ginsenosides such as Rh2, Rg5, Rk1, and Rh4...

🗓️ 2026-07-03
📰 Publication: Journal Of Ginseng Research
Read MoreLi-ginseng powder alleviates cancer cachexia in mice by regulating the ubiquitin-proteasome pathway and reducing inflammation.

Myovascular Niche: The Role of Endothelial Cells in Skeletal Muscle Health and Disease.

Skeletal muscle health and regeneration are highly orchestrated processes governed by a complex interplay of muscle stem cells, fibro-adipogenic progenitors, immune cells, and endothelial cells. Among these cell types, endothelial cells play a central role not only by regulating blood...

🗓️ 2026-07-02
📰 Publication: Circulation Research
Read MoreMyovascular Niche: The Role of Endothelial Cells in Skeletal Muscle Health and Disease.

Functional Outcomes and Quality of Life for Patients With Cachexia and Solid Tumour Cancers: Findings of a Systematic Literature Review.

BACKGROUND

Cachexia, a complex multifactorial syndrome characterized by loss of skeletal muscle mass, is common in cancer and impacts treatment response, quality of life (QoL) and survival. No effective therapy is currently available. This report summarizes findings from the literature on...

🗓️ 2026-06-30
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreFunctional Outcomes and Quality of Life for Patients With Cachexia and Solid Tumour Cancers: Findings of a Systematic Literature Review.

Icariin ameliorates sarcopenia via activation of the estrogen receptor α/fatty acid transport protein 1 pathway.

BACKGROUND

Sarcopenia is a prevalent disorder among postmenopausal women, representing a debilitating condition with limited treatment options. Icariin (ICA), a prenylated flavonol glycoside, is commonly used in conditions associated with estrogen deficiency; however, its efficacy and mechanism in postmenopausal sarcopenia remain...

🗓️ 2026-06-25
📰 Publication: Phytomedicine
Read MoreIcariin ameliorates sarcopenia via activation of the estrogen receptor α/fatty acid transport protein 1 pathway.

Combination Therapy with Bisoprolol and Tissue Protective Molecule ARA 284 Is Cardio-Protective and Improves Survival in Experimental Cancer Cachexia.

BACKGROUND

Cancer cachexia is a serious condition during the last stages of the disease, which is characterized by the loss of muscle and fat mass in patients with cancer. There are no effective treatments for cancer cachexia, and new treatment interventions...

🗓️ 2026-06-25
Read MoreCombination Therapy with Bisoprolol and Tissue Protective Molecule ARA 284 Is Cardio-Protective and Improves Survival in Experimental Cancer Cachexia.

3,3'-Diindolylmethane ameliorates muscle atrophy by modulating mitochondrial function and calcium homeostasis.

BACKGROUND

Sarcopenia is a chronic degenerative condition characterized by the progressive loss of muscle mass and function. Current therapeutic strategies exhibit limited therapeutic efficacy and present substantial challenges in ensuring sustained patient compliance. Although mitochondrial dysfunction is a confirmed biomarker of...

🗓️ 2026-06-18
📰 Publication: Phytomedicine
Read More3,3'-Diindolylmethane ameliorates muscle atrophy by modulating mitochondrial function and calcium homeostasis.

Creatine/Creatinine Ratio and Myostatin as Biomarkers to Monitor Muscle Function in Duchenne Muscular Dystrophy Patients.

BACKGROUND

Duchenne Muscular Dystrophy (DMD) is characterized by progressive muscle wasting leading to early loss of motor function. Functional tests monitor disease progression and serve as clinical trial endpoints but are influenced by maturation in younger patients, high intra-patient variability and...

🗓️ 2026-06-16
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCreatine/Creatinine Ratio and Myostatin as Biomarkers to Monitor Muscle Function in Duchenne Muscular Dystrophy Patients.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!